4 results
1. To determine the efficacy of CJM112 300 mg in chronic hidradenitis suppurativa (HS) patients, by clinical responder rate at week 16.2. To assess the safety and tolerability of CJM112 in patients with chronic hidradenitis suppurativa (HS)3. To…
Primary Objective: The primary objective for this study is to compare the efficacy of ABP 215 with bevacizumab.Secondary Objective(s): The secondary objectives are to assess the safety and immunogenicity of ABP 215 compared with bevacizumab.
To develop a PKPD dexmedetomidine model, and to assess the effect of continuous auditory stimulation on dexmedetomidine pharmacodynamics.
The study is designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition,…